Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$88.2 million.

  • Agios Pharmaceuticals' Cash from Operations fell 467.0% to -$88.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$409.9 million, marking a year-over-year decrease of 2453.78%. This contributed to the annual value of -$389.8 million for FY2024, which is 3167.55% down from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Cash from Operations is -$88.2 million, which was down 467.0% from -$77.1 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Cash from Operations' 5-year high stood at -$61.6 million during Q3 2023, with a 5-year trough of -$133.2 million in Q4 2024.
  • Over the past 5 years, Agios Pharmaceuticals' median Cash from Operations value was -$84.2 million (recorded in 2024), while the average stood at -$88.4 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Cash from Operations skyrocketed by 3671.54% in 2022 and then plummeted by 8370.9% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Operations (Quarter) stood at -$84.1 million in 2021, then rose by 21.32% to -$66.2 million in 2022, then fell by 9.56% to -$72.5 million in 2023, then tumbled by 83.71% to -$133.2 million in 2024, then soared by 33.8% to -$88.2 million in 2025.
  • Its Cash from Operations stands at -$88.2 million for Q3 2025, versus -$77.1 million for Q2 2025 and -$111.5 million for Q1 2025.